苦参膜治疗产后阴道菌群失调的多中心双盲随机对照试验方案
本研究为多中心、随机、双盲、安慰剂对照临床试验,计划纳入292例产后阴道菌群失调(PVD)患者,随机接受苦参膜(每片含100 mg氧化苦参碱)或安慰剂阴道给药,每日一次连续7天。主要结局为PVD改善的治疗疗效,次要结局包括阴道健康评分、炎症评分、生活质量、阴道炎症生物标志物、不良事件及治疗相关费用,并采用决策树模型进行成本-效果分析。
要点
- 苦参膜每片含100 mg氧化苦参碱,阴道给药每日一次连续7天。
- 主要结局为PVD治疗疗效,次要结局涵盖阴道健康评分、炎症评分及生活质量等。
- 将采用决策树模型从患者视角进行成本-效果分析。
核心结论
- 该试验旨在评估苦参膜治疗产后阴道菌群失调的安全性、疗效和成本-效果。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验,计划从中国四家三级医院纳入292例PVD患者。
- 参与者随机接受苦参膜或安慰剂,阴道给药每日一次连续7天,每片含100 mg氧化苦参碱。
关键数值与推荐
- 主要结局为苦参膜改善PVD的治疗疗效。
- 次要结局包括阴道健康评分、阴道炎症评分、生活质量、阴道炎症生物标志物水平、不良事件发生率及治疗相关费用。
- 分析采用多变量逻辑回归模型和协方差分析(ANCOVA),并从患者视角使用决策树模型进行成本-效果分析(CEA)。
局限性
- 研究结果可能受主观判断和区域局限性影响。
- 未来需要多中心研究验证治疗疗效,以优化临床决策和经济评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The vaginal microecological barrier in postpartum women is particularly vulnerable, and its stability plays a crucial role in maintaining reproductive tract health. Emerging evidence indicates that Sophora flavescens films (SFF) may have therapeutic potential in managing postpartum vaginal dysbiosis (PVD). This study is therefore designed to evaluate the safety, efficacy, and cost-effectiveness of SFF in the treatment of PVD. METHODS AND ANALYSIS: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 292 participants diagnosed with PVD will be enrolled from four tertiary hospitals across China. Eligible participants will be randomly assigned to receive either SFF or a placebo, administered intravaginally once daily for seven consecutive days (each film contains 100 mg of oxymatrine). The primary outcome is the therapeutic efficacy of SFF in improving PVD. Secondary outcomes include changes in vaginal health scores, vaginal inflammation scores, quality of life, levels of vaginal inflammatory biomarkers, incidence of adverse events, and treatment-related costs. Multivariable logistic regression models and analysis of covariance (ANCOVA) will be employed for analysis. Furthermore, a cost-effectiveness analysis (CEA) from the patient's perspective will be performed using a decision tree model to evaluate the pharmacoeconomic profile of SFF. DISCUSSION: This study provides evidence-based insights into clinical interventions for PVD. It uses standardized assessment criteria and a double-blind design. However, the findings may be influenced by subjective judgment and regional limitations. Future multicenter studies are needed. They will validate therapeutic efficacy. This will help optimize clinical decision-making and economic evaluations. TRIAL REGISTRATION: The study is registered at http://www.chictr.org.cn (ChiCTR2500102388, 14 May 2025).
引用
- Huang Y, Tan S, Li X, et al. Efficacy, safety, and cost-effectiveness of Sophora flavescens films in the treatment of postpartum vaginal dysbiosis in women (SFF-PVD Study): study protocol for a multicenter double-blind randomized controlled trial. Trials. 2026. PMID: 41975446. doi:10.1186/s13063-026-09707-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。